Moderna’s, $MRNA, CEO has said that the company will no longer invest in new Phase 3 vaccine trials for infectious diseases: ‘You cannot make a return on investment if you don’t have access to the U.S. market.’ Vaccines for Epstein-Barr virus, herpes, and shingles have been